|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Cefotetan disodium]] |
| {{Cefotetan}}
| |
| {{CMG}};{{AE}}{{AK}}
| |
| | |
| | |
| '''''For patient information, click <u>[[Cefotetan Disodium(patient information)|here]]'''''</u>
| |
| ==Overview==
| |
| '''Cefotetan''' is an injectable [[antibiotic]] of the [[cephamycin]] type for prophylaxis and treatment of [[bacterial infection]]s. It is often grouped together with second-generation [[cephalosporin]]s and has a similar antibacterial spectrum, but with additional anti-anaerobe converage.
| |
| | |
| Cefotetan was developed by [[Yamanouchi]]. It is marketed outside Japan by [[AstraZeneca]] with the brand names '''Apatef''' and '''Cefotan'''.
| |
| | |
| | |
| ==Category==
| |
| [[Cephalosporins]], second generation.
| |
| | |
| | |
| ==US Brand Names==
| |
| | |
| CEFOTETAN®
| |
| | |
| ==FDA Package Insert==
| |
| ''' [[Cefotetan description|Description]]'''
| |
| '''| [[Cefotetan clinical pharmacology|Clinical Pharmacology]]'''
| |
| '''| [[Cefotetan microbiology|Microbiology]]'''
| |
| '''| [[Cefotetan indications and usage|Indications and Usage]]'''
| |
| '''| [[Cefotetan contraindications|Contraindications]]'''
| |
| '''| [[Cefotetan warnings and precautions|Warnings and Precautions]]'''
| |
| '''| [[Cefotetan adverse reactions|Adverse Reactions]]'''
| |
| '''| [[Cefotetan overdosage|Overdosage]]'''
| |
| '''| [[Cefotetan clinical studies|Clinical Studies]]'''
| |
| '''| [[Cefotetan dosage and administration|Dosage and Administration]]'''
| |
| '''| [[Cefotetan Compatibility and Stability|Compatibility and Stability]]'''
| |
| '''| [[Cefotetan how supplied|How Supplied]]'''
| |
| '''| [[Cefotetan labels and packages|Labels and Packages]]'''
| |
| | |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/50588slr027_cefotan_lbl.pdf
| |
| [[Category:Antibiotics]]
| |
| [[Category:Wikinfect]]
| |